Conference Coverage
Latest News
Jul 31, 2026 | Opinion
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
Testosterone deficiency: FAQs from the AUA guideline
Jul 30, 2026
From hype to practice: Urologists assess AI's real impact
Jul 30, 2026
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
Jul 30, 2026
Pearls & Perspectives: From Prostate Cancer Diagnosis to Patient Advocacy, with Gabe Canales
Jul 29, 2026
Advertisement
Shorts
1:08
Janelle Bunce, PA-C, discusses a holistic approach to testosterone deficiency care
an hour ago
by
Janelle Bunce, PA-C
0:45
Matthew Galsky, MD, on the changing role of cisplatin eligibility in MIBC
a day ago
by
Matthew Galsky, MD
0:29
Joshua Halpern, MD, on what’s next in male fertility diagnostics
2 days ago
by
Joshua Halpern, MD, MS
1:02
EV/pembro toxicity: What patients need to know upfront
3 days ago
by
María Natalia Gandur Quiroga, MD, MSc
1:33
The UroOnc Minute: Using physician data to improve patient outcomes
4 days ago
by
Adam B. Weiner, MD(+1 more)
1:07
Debra L. Fromer, MD, highlights efficacy data on tebipenem pivoxil for cUTI
7 days ago
by
Debra L. Fromer, MD
0:52
Beyond trial and error: The future of functional urology
8 days ago
by
Sasha Vereecken, RN
1:04
How the BRIDGE trial may impact bladder cancer treatment
9 days ago
by
Tyler Garman, MD
0:38
A new perioperative standard emerges for MIBC
10 days ago
by
María Natalia Gandur Quiroga, MD, MSc
1:15
Matthew Galsky, MD, explains the significance of perioperative EV/pembro in MIBC
11 days ago
by
Matthew Galsky, MD
From GSM guidance to HRT reform: A landmark year for women’s health
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
Inguinal lymph node dissection in penile cancer
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
Inside HoLEP: Irina Jaeger, MD, discusses patient selection and technique
Jaeger emphasizes that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication.
Podcasts
Videos
Urology Times Digital Edition
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.
The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Continuing Medical Education
Advertisement
All News
Advertisement
Matthew D. Galsky, MD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab for MIBC is moving the field beyond cisplatin eligibility and influencing future approaches to surgery and response-guided therapy.
Adanma Ayanambakkam, MD, MS, highlights data from the phase 1 FIT-001 trial evaluating darlifarnib plus cabozantinib in patients with advanced renal cell carcinoma.
This FAQ outlines the major recommendations from PCWG4 for urologists and clinical investigators involved in prostate cancer clinical trials.
Phase 3 BOND-003 data published in The Lancet Oncology showed that intravesical cretostimogene grenadenorepvec produced durable complete responses and a favorable safety profile in patients with high-risk, BCG-unresponsive NMIBC with CIS.
Experts discuss why accurately recognizing CIS in patients with suspected NMIBC is essential to preventing disease progression, guiding surveillance, and expanding treatment and clinical trial opportunities.
Darlifarnib plus cabozantinib demonstrated encouraging antitumor activity with a manageable safety profile in patients with ccRCC, including both cabozantinib-naive and cabozantinib-exposed populations.
Joshua Halpern, MD, MS, reviews evidence supporting the accuracy of mail-in semen analysis and identifies patients who may benefit most from at-home testing.
CAPTAIN trial data showed TULSA preserved penile length, continence, and erectile function compared with robotic prostatectomy in localized prostate cancer.
In this episode, Jason Hafron, MD, explains how data-driven pathways and patient follow-up systems can improve quality and outcomes in urologic oncology.
Can Aydogdu, MD, highlights a study examining the utility of pre-surgical tumor-informed ctDNA to predict pathologic nodal status at radical cystectomy.
Advertisement
The PDUFA target action date is in the fourth quarter of 2026.
The study showed that perioperative EV–pembrolizumab improved EFS, OS, and pCR rate vs neoadjuvant cisplatin-gemcitabine in patients with MIBC who are eligible for cisplatin-based chemotherapy.
Experts discuss practical strategies to improve the detection of CIS through closer urologist-pathologist collaboration, optimized biopsy techniques, and complementary diagnostic tools.
Olaparib's indications in the US include use as a single agent for patients with HRR gene-mutated mCRPC and in combination with abiraterone and prednisone for patients with BRCA-mutated mCRPC.
These results provided the basis for the ongoing randomized phase 3 ProstACT Global trial evaluating 177Lu-rosopatamab tetraxetan in mCRPC.
Advertisement
Advertisement
Trending on Urology Times
1
Testosterone deficiency: FAQs from the AUA guideline
2
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
3
From hype to practice: Urologists assess AI's real impact
4
Matthew Galsky, MD, on how EV/pembrolizumab is redefining the MIBC treatment paradigm
5